Symbols / ENTX $1.00 -11.50% Entera Bio Ltd.

Healthcare • Biotechnology • Israel • NCM
ENTX Chart
About

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 45.86M
Enterprise Value 43.46M Income -10.78M Sales 124.00K
Book/sh 0.33 Cash/sh 0.19 Dividend Yield —
Payout 0.00% Employees 20 IPO —
P/E — Forward P/E -1.82 PEG —
P/S 369.82 P/B 2.99 P/C —
EV/EBITDA -4.03 EV/Sales 350.45 Quick Ratio 5.46
Current Ratio 10.83 Debt/Eq 1.39 LT Debt/Eq —
EPS (ttm) -0.25 EPS next Y -0.55 EPS Growth —
Revenue Growth — Earnings 2026-03-27 16:00 ROA -53.80%
ROE -99.43% ROIC — Gross Margin 0.00%
Oper. Margin -87.29% Profit Margin 0.00% Shs Outstand 45.86M
Shs Float 31.32M Short Float 0.35% Short Ratio 1.42
Short Interest — 52W High 3.22 52W Low 0.91
Beta 1.48 Avg Volume 208.43K Volume 302.52K
Target Price $10.00 Recom None Prev Close $1.13
Price $1.00 Change -11.50%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-4.62
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-09 reit HC Wainwright & Co. Buy → Buy $10
2025-03-18 reit HC Wainwright & Co. Buy → Buy $10
2024-11-11 reit HC Wainwright & Co. Buy → Buy $10
2024-10-07 reit HC Wainwright & Co. Buy → Buy $10
2024-09-27 reit HC Wainwright & Co. Buy → Buy $10
2024-08-12 reit HC Wainwright & Co. Buy → Buy $10
2024-06-05 reit HC Wainwright & Co. Buy → Buy $10
2024-05-14 reit HC Wainwright & Co. Buy → Buy $10
2024-05-13 reit HC Wainwright & Co. Buy → Buy $10
2024-04-02 main HC Wainwright & Co. Buy → Buy $10
2023-12-11 reit HC Wainwright & Co. Buy → Buy $10
2023-09-13 reit HC Wainwright & Co. Buy → Buy $10
2023-09-11 reit HC Wainwright & Co. Buy → Buy $10
2023-05-08 reit HC Wainwright & Co. — → Buy $10
2023-04-04 reit HC Wainwright & Co. — → Buy $10
2023-03-28 reit HC Wainwright & Co. — → Buy $10
2022-09-06 init HC Wainwright & Co. — → Buy $10
2022-07-19 main B. Riley Securities — → Buy $5
2021-06-16 init B. Riley Securities — → Buy $9
2021-03-22 init Aegis Capital — → Buy $12
News
RSS: Latest ENTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-09 GERMANO GENO J Director — 20,000 $1.30 $26,000
2026-03-05 ELLIS SEAN Director — 10,000 $1.23 $12,300
2026-02-12 RUBIN STEVEN DANIEL Director — 5,000 $1.49 $7,450
2026-02-10 GERMANO GENO J Director — 20,000 $1.49 $29,800
2026-02-10 TAITEL HAYA Director — 7,500 $1.48 $11,100
2026-02-09 RUBIN STEVEN DANIEL Director — 10,000 $1.20 $12,000
2026-02-09 ELLIS SEAN Director — 18,000 $1.24 $22,320
2025-12-31 LIEBERMAN GERALD M Director — 38,294 $0.00 $0
2025-12-31 OSTROV GERALD M Director — 28,721 $0.00 $0
2025-12-31 ELLIS SEAN Director — 25,371 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.18
0.00
-100.00%
0.13
-76.53%
0.57
Operating Revenue
0.18
0.00
-100.00%
0.13
-76.53%
0.57
Cost Of Revenue
0.17
0.00
-100.00%
0.10
-72.92%
0.37
Reconciled Cost Of Revenue
0.17
0.00
-100.00%
0.10
-72.92%
0.37
Gross Profit
0.01
0.00
-100.00%
0.03
-83.33%
0.20
Operating Expense
9.59
+7.91%
8.89
-31.87%
13.05
+5.11%
12.41
Research And Development
4.50
-0.24%
4.51
-22.88%
5.85
-13.63%
6.77
Selling General And Administration
5.09
+15.01%
4.43
-38.92%
7.25
+27.47%
5.69
General And Administrative Expense
5.09
+15.01%
4.43
-38.92%
7.25
+27.47%
5.69
Other Gand A
5.09
+15.01%
4.43
-38.92%
7.25
+27.47%
5.69
Other Operating Expenses
—
-0.05
+3.92%
-0.05
-10.87%
-0.05
Total Expenses
9.77
+9.84%
8.89
-32.39%
13.15
+2.84%
12.79
Operating Income
-9.59
-7.81%
-8.89
+31.70%
-13.02
-6.55%
-12.22
Total Operating Income As Reported
-9.59
-7.81%
-8.89
+31.70%
-13.02
-6.55%
-12.22
EBITDA
-9.54
-7.97%
-8.84
+31.79%
-12.95
-6.49%
-12.16
Normalized EBITDA
-9.54
-7.97%
-8.84
+31.79%
-12.95
-6.49%
-12.16
Reconciled Depreciation
0.05
-17.86%
0.06
-12.50%
0.06
+20.75%
0.05
EBIT
-9.59
-7.81%
-8.89
+31.70%
-13.02
-6.55%
-12.22
Net Income
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Pretax Income
-9.53
-7.53%
-8.86
+31.50%
-12.93
-5.62%
-12.25
Net Non Operating Interest Income Expense
0.06
+87.10%
0.03
-62.65%
0.08
+386.21%
-0.03
Interest Expense Non Operating
—
—
—
0.03
Net Interest Income
0.06
+87.10%
0.03
-62.65%
0.08
+386.21%
-0.03
Interest Expense
—
—
—
0.03
Tax Provision
0.01
-51.72%
0.03
-78.83%
0.14
+332.20%
-0.06
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+4258.66%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Net Income From Continuing Operation Net Minority Interest
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Net Income From Continuing And Discontinued Operation
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Net Income Continuous Operations
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Normalized Income
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Net Income Common Stockholders
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Diluted EPS
-0.25
+19.35%
-0.31
+31.11%
-0.45
+4.26%
-0.47
Basic EPS
-0.25
+19.35%
-0.31
+31.11%
-0.45
+4.26%
-0.47
Basic Average Shares
37.65
+29.79%
29.01
+0.69%
28.81
+10.23%
26.13
Diluted Average Shares
37.65
+29.79%
29.01
+0.69%
28.81
+10.23%
26.13
Diluted NI Availto Com Stockholders
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Total Other Finance Cost
-0.06
-87.10%
-0.03
+62.65%
-0.08
-386.21%
0.03
Line Item Trend 2023-12-31
Total Assets
11.77
Current Assets
11.26
Cash Cash Equivalents And Short Term Investments
11.02
Cash And Cash Equivalents
11.02
Receivables
0.00
Accounts Receivable
0.00
Other Current Assets
0.24
Total Non Current Assets
0.51
Net PPE
0.49
Gross PPE
0.49
Other Properties
0.49
Non Current Deferred Assets
0.01
Non Current Deferred Taxes Assets
0.01
Other Non Current Assets
—
Total Liabilities Net Minority Interest
1.38
Current Liabilities
1.09
Payables And Accrued Expenses
0.58
Payables
0.08
Accounts Payable
0.08
Current Accrued Expenses
0.50
Employee Benefits
0.03
Pensionand Other Post Retirement Benefit Plans Current
0.37
Total Tax Payable
—
Income Tax Payable
—
Current Debt And Capital Lease Obligation
0.13
Current Capital Lease Obligation
0.13
Current Deferred Liabilities
—
Current Deferred Revenue
—
Total Non Current Liabilities Net Minority Interest
0.29
Long Term Debt And Capital Lease Obligation
0.26
Long Term Capital Lease Obligation
0.26
Defined Pension Benefit
0.01
Non Current Pension And Other Postretirement Benefit Plans
0.03
Stockholders Equity
10.39
Common Stock Equity
10.39
Capital Stock
0.00
Common Stock
0.00
Share Issued
35.48
Ordinary Shares Number
35.48
Treasury Shares Number
0.00
Additional Paid In Capital
114.73
Retained Earnings
-104.39
Gains Losses Not Affecting Retained Earnings
0.04
Other Equity Adjustments
0.04
Total Equity Gross Minority Interest
10.39
Total Capitalization
10.39
Working Capital
10.17
Invested Capital
10.39
Total Debt
0.39
Capital Lease Obligations
0.39
Net Tangible Assets
10.39
Tangible Book Value
10.39
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-6.82
+6.73%
-7.31
+41.52%
-12.50
-37.91%
-9.06
Cash Flow From Continuing Operating Activities
-6.82
+6.73%
-7.31
+41.52%
-12.50
-37.91%
-9.06
Net Income From Continuing Operations
-9.54
-7.33%
-8.89
+31.99%
-13.07
-7.25%
-12.19
Depreciation Amortization Depletion
0.05
-17.86%
0.06
-12.50%
0.06
+20.75%
0.05
Depreciation
0.05
-17.86%
0.06
-12.50%
0.06
+20.75%
0.05
Depreciation And Amortization
0.05
-17.86%
0.06
-12.50%
0.06
+20.75%
0.05
Other Non Cash Items
-0.01
—
-0.08
-533.33%
0.02
Stock Based Compensation
2.56
+51.33%
1.69
-24.83%
2.25
+20.74%
1.86
Deferred Tax
0.01
-51.72%
0.03
-83.33%
0.17
+180.18%
-0.22
Deferred Income Tax
0.01
-51.72%
0.03
-83.33%
0.17
+180.18%
-0.22
Change In Working Capital
0.11
+157.44%
-0.20
+89.37%
-1.83
-230.23%
1.41
Change In Receivables
-0.13
-151.22%
0.25
+490.48%
-0.06
-187.50%
0.07
Changes In Account Receivables
-0.13
-151.22%
0.25
+490.48%
-0.06
-187.50%
0.07
Change In Payables And Accrued Expense
0.25
+150.70%
-0.50
+71.05%
-1.72
-216.56%
1.47
Change In Accrued Expense
0.20
+136.06%
-0.56
+64.09%
-1.57
-206.59%
1.47
Change In Payable
0.05
-25.76%
0.07
+144.30%
-0.15
-7550.00%
0.00
Change In Account Payable
0.05
-25.76%
0.07
+144.30%
-0.15
-7550.00%
0.00
Change In Other Working Capital
—
—
-0.01
+89.51%
-0.14
Change In Other Current Assets
-0.01
-125.00%
0.06
+240.00%
-0.04
-671.43%
0.01
Investing Cash Flow
-0.00
+82.35%
-0.02
+83.33%
-0.10
-500.00%
-0.02
Cash Flow From Continuing Investing Activities
-0.00
+82.35%
-0.02
+83.33%
-0.10
-500.00%
-0.02
Net PPE Purchase And Sale
-0.00
+82.35%
-0.02
+63.83%
-0.05
-176.47%
-0.02
Purchase Of PPE
-0.00
+82.35%
-0.02
+63.83%
-0.05
-176.47%
-0.02
Capital Expenditure
-0.00
+82.35%
-0.02
+63.83%
-0.05
-176.47%
-0.02
Net Other Investing Changes
—
—
-0.06
—
Financing Cash Flow
4.48
-25.84%
6.04
+46330.77%
0.01
-99.95%
25.38
Cash Flow From Continuing Financing Activities
4.48
-25.84%
6.04
+46330.77%
0.01
-99.95%
25.38
Net Common Stock Issuance
3.96
-40.15%
6.62
0.00
-100.00%
21.80
Proceeds From Stock Option Exercised
0.84
0.00
-100.00%
0.01
-99.64%
3.58
Net Other Financing Charges
-0.32
+44.31%
-0.58
—
—
Changes In Cash
-2.35
-81.64%
-1.29
+89.74%
-12.59
-177.22%
16.30
Beginning Cash Position
11.09
-10.43%
12.38
-50.42%
24.96
+188.17%
8.66
End Cash Position
8.74
-21.15%
11.09
-10.43%
12.38
-50.42%
24.96
Free Cash Flow
-6.82
+6.91%
-7.33
+41.60%
-12.55
-38.17%
-9.08
Income Tax Paid Supplemental Data
—
0.00
-100.00%
0.17
+8150.00%
0.00
Common Stock Issuance
3.96
-40.15%
6.62
0.00
-100.00%
21.80
Issuance Of Capital Stock
3.96
-40.15%
6.62
0.00
-100.00%
21.80
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category